跳至主要内容
临床试验/EUCTR2010-020122-18-SE
EUCTR2010-020122-18-SE进行中(未招募)不适用

A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors

Bayer HealthCare AG0 个研究点目标入组 267 人开始时间: 2010年8月31日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
267

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • Open-label run-in phase (first four weeks)
  • Written informed consent signed before any study-specific procedure
  • History of ED for at least 6 months prior to screening, defined as the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse; the diagnosis of ED has to be confirmed by a physician
  • Stable, heterosexual relationship for at least 6 months prior to screening
  • Aged 18 to 64 years (inclusive) at the first screening examination
  • History of previous use of at least 1 marketed PDE5 inhibitor and insufficient therapeutic efficacy despite use of the highest approved dose
  • Double-blind treatment phase (last four weeks)
  • At least 4 attempts at sexual intercourse on 4 separate days during the open-label run-in phase with use of 20 mg vardenafil approximately 1 hour before attempting intercourse
  • IIEF EF score <17
  • At least 50% of attempts at sexual intercourse during the open-label run-in phase were unsuccessful
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Contraindication to use of vardenafil
  • History of prostatectomy due to prostate cancer, including nerve-sparing techniques.
  • Concomitant use of adrenergic blockers
  • History of spinal cord injury
  • Resting hypotension, i.e. SBP <100 mmHg at rest
  • Moderate / severe hypertension, i.e. SBP >170 mmHg or DBP >110 mmHg at rest
  • Symptomatic orthostatic hypotension with a decrease in SBP >20 mmHg or in DBP >10 mmHg subsequent to change from the supine to standing position
  • History of pelvic radiotherapy
  • Pulmonary venous occlusive disease

研究者

相似试验

进行中(未招募)
不适用
A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors
EUCTR2010-020122-18-FIBayer HealthCare AG267
已完成
2 期
A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors
NL-OMON34486Bayer30
进行中(未招募)
不适用
A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors - ND
EUCTR2010-020122-18-ITBayer HealthCare AG267
进行中(未招募)
1 期
A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitors
EUCTR2010-020122-18-NLBayer HealthCare AG
进行中(未招募)
1 期
A prospective, randomized, double-blind, double-dummy, placebo- and active controlled, multicenter study assessing the efficacy and safety of the combination BAY 60 4552 / vardenafil compared to vardenafil (20 mg) for the treatment of erectile dysfunction not sufficiently responsive to standard therapy with PDE5 inhibitorsErectile dysfunctionMedDRA version: 12.1Level: LLTClassification code 10061461Term: Erectile dysfunction
EUCTR2010-020122-18-FRBayer HealthCare AG